AIMS: Ghrelin is a gastric-derived hormone that stimulates growth hormone (GH) secretion and has a multi-faceted role in the regulation of energy homeostasis, including glucose metabolism. Circulating ghrelin concentrations are modulated in response to nutritional status, but responses to ghrelin in altered metabolic states are poorly understood. We investigated the metabolic effects of ghrelin in obesity and early after Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: We assessed central and peripheral metabolic responses to acyl ghrelin infusion (1 pmol kg-1 min-1 ) in healthy, lean subjects (n = 9) and non-diabetic, obese subjects (n = 9) before and 2 weeks after RYGB. Central responses were assessed by GH and pancreatic polypeptide (surrogate for vagal activity) secretion. Peripheral responses were assessed by hepatic and skeletal muscle insulin sensitivity during a hyperinsulinaemic-euglycaemic clamp. RESULTS:Ghrelin-stimulated GH secretion was attenuated in obese subjects, but was restored by RYGB to a response similar to that of lean subjects. The heightened pancreatic polypeptide response to ghrelin infusion in the obese was attenuated after RYGB. Hepatic glucose production and hepatic insulin sensitivity were not altered by ghrelin infusion in RYGB subjects. Skeletal muscle insulin sensitivity was impaired to a similar degree in lean, obese and post-RYGB individuals in response to ghrelin infusion. CONCLUSIONS: These data suggest that obesity is characterized by abnormal central, but not peripheral, responsiveness to ghrelin that can be restored early after RYGB before significant weight loss. Further work is necessary to fully elucidate the role of ghrelin in the metabolic changes that occur in obesity and following RYGB.
RCT Entities:
AIMS: Ghrelin is a gastric-derived hormone that stimulates growth hormone (GH) secretion and has a multi-faceted role in the regulation of energy homeostasis, including glucose metabolism. Circulating ghrelin concentrations are modulated in response to nutritional status, but responses to ghrelin in altered metabolic states are poorly understood. We investigated the metabolic effects of ghrelin in obesity and early after Roux-en-Y gastric bypass (RYGB). MATERIALS AND METHODS: We assessed central and peripheral metabolic responses to acyl ghrelin infusion (1 pmol kg-1 min-1 ) in healthy, lean subjects (n = 9) and non-diabetic, obese subjects (n = 9) before and 2 weeks after RYGB. Central responses were assessed by GH and pancreatic polypeptide (surrogate for vagal activity) secretion. Peripheral responses were assessed by hepatic and skeletal muscle insulin sensitivity during a hyperinsulinaemic-euglycaemic clamp. RESULTS:Ghrelin-stimulated GH secretion was attenuated in obese subjects, but was restored by RYGB to a response similar to that of lean subjects. The heightened pancreatic polypeptide response to ghrelin infusion in the obese was attenuated after RYGB. Hepatic glucose production and hepatic insulin sensitivity were not altered by ghrelin infusion in RYGB subjects. Skeletal muscle insulin sensitivity was impaired to a similar degree in lean, obese and post-RYGB individuals in response to ghrelin infusion. CONCLUSIONS: These data suggest that obesity is characterized by abnormal central, but not peripheral, responsiveness to ghrelin that can be restored early after RYGB before significant weight loss. Further work is necessary to fully elucidate the role of ghrelin in the metabolic changes that occur in obesity and following RYGB.
Authors: Kenneth A Longo; Elizabeth K Govek; Anna Nolan; Thomas McDonagh; Soratree Charoenthongtrakul; Derek J Giuliana; Kristen Morgan; Jeffrey Hixon; Chaoseng Zhou; Bruce Kelder; John J Kopchick; Jeffrey O Saunders; Manuel A Navia; Rory Curtis; Peter S DiStefano; Brad J Geddes Journal: J Pharmacol Exp Ther Date: 2011-07-20 Impact factor: 4.030
Authors: M R Druce; A M Wren; A J Park; J E Milton; M Patterson; G Frost; M A Ghatei; C Small; S R Bloom Journal: Int J Obes (Lond) Date: 2005-09 Impact factor: 5.095
Authors: Jenny Tong; Ronald L Prigeon; Harold W Davis; Martin Bidlingmaier; Matthias H Tschöp; David D'Alessio Journal: J Clin Endocrinol Metab Date: 2013-04-15 Impact factor: 5.958
Authors: Jianhua Liu; Catherine E Prudom; Ralf Nass; Suzan S Pezzoli; Mary C Oliveri; Michael L Johnson; Paula Veldhuis; David A Gordon; Andrew D Howard; Derrick R Witcher; H Mario Geysen; Bruce D Gaylinn; Michael O Thorner Journal: J Clin Endocrinol Metab Date: 2008-03-18 Impact factor: 5.958
Authors: Mary R Lee; Mehdi Farokhnia; Enoch Cobbina; Anitha Saravanakumar; Xiaobai Li; Jillian T Battista; Lisa A Farinelli; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Neuropharmacology Date: 2019-09-23 Impact factor: 5.250
Authors: S Ezquerro; S Becerril; C Tuero; L Méndez-Giménez; F Mocha; R Moncada; V Valentí; J A Cienfuegos; V Catalán; J Gómez-Ambrosi; K Piper Hanley; G Frühbeck; A Rodríguez Journal: Int J Obes (Lond) Date: 2019-07-19 Impact factor: 5.095
Authors: Alanna S Thomas; Martina Sassi; Roberto Angelini; Alwena H Morgan; Jeffrey S Davies Journal: Front Physiol Date: 2022-06-30 Impact factor: 4.755
Authors: Mehdi Farokhnia; Kelly M Abshire; Aaron Hammer; Sara L Deschaine; Anitha Saravanakumar; Enoch Cobbina; Zhi-Bing You; Carolina L Haass-Koffler; Mary R Lee; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Int J Neuropsychopharmacol Date: 2021-07-14 Impact factor: 5.176